Melanocortin receptor agonist
PT-141 (bremelanotide)
Non-selective (notably MC4R) used as a labelled on-demand therapy for hypoactive sexual desire disorder in some markets.
Primary Mechanism of Action
Clinical / Scientific
PT-141 (bremelanotide) activates central receptors, especially MC4R, modulating sexual-desire circuitry independently of -mediated genital vasodilation. Nausea via MC receptors is a class effect.
Pathway Targets
MC4 receptor
Scientific explanation
Central agonism linked to sexual-function signalling.
Pathway Convergence
Clinical / Scientific
Target → pathway → downstream effect → biological consequence. This is a mechanistic map, not a treatment claim.
Receptor to physiology
Target to downstream effect: MC4 receptor
Mechanistically Relevant Repurposed & Adjunctive Applications
Hypoactive sexual desire disorder (labelled bremelanotide)
EstablishedMechanistic rationale
Approved in some markets as injectable bremelanotide. Research vials are not automatically the licensed drug-device presentation.
Mechanistic Application Matrix
| Biological Target | Mechanism | Potential Relevance | Evidence Level |
|---|---|---|---|
| MC4R | Agonism | Central sexual-function circuits | Established mechanism |
Mechanistic Interaction Considerations
Blood-pressure increases are labelled. Not a substitute for purely vasculogenic ED; mechanisms differ.
In Plain Language
PT-141 turns on (MC4) receptors in the brain that are involved in sexual desire, unlike tadalafil which works on blood-vessel enzymes in the penis.
Compounds Sharing Pathways
Other library compounds whose structured pathway data overlap this ingredient. Shared pathways are not combination recommendations.
MC4 receptor
Mechanistic information is provided for scientific and educational purposes. Discussion of biological pathways or investigational applications does not establish clinical efficacy or constitute individualized medical advice.